Linked Life Data

16572113

Source:http://linkedlifedata.com/resource/pubmed/id/16572113

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-5-11
pubmed:abstractText
According to the concept of apolipoprotein (apo)-defined lipoproteins, apoA-I-containing lipoproteins consist of two subclasses referred to as lipoprotein A-I (LpA-I) and lipoprotein A-I:A-II (LpA-I:A-II), and apoB-containing lipoproteins of five subclasses, namely lipoprotein B (LpB), lipoprotein B:C (LpB:C), lipoprotein B:E (LpB:E), lipoprotein B:C:E (LpB:C:E), and lipoprotein A-II:B:C:D:E (LpA-II:B:C:D:E). The purpose of this study was to determine the levels of apoA-I- and apoB-containing lipoprotein subclasses before and after fluvastatin treatment of patients with chronic renal insufficiency. ApoA-I- and apoB-containing lipoprotein subclasses were measured in 15 patients with chronic renal failure and 15 asymptomatic subjects. The effect of fluvastatin on lipoprotein subclasses was determined in a randomized, double-blind, placebo-controlled, two-way, treatment period crossover study. Patients were administered fluvastatin 40 mg/day or placebo during 8 weeks in a randomized order. Patients were characterized by significantly higher levels of LpB (P < 0.001), LpB:C (P < 0.001), and LpB:E (P < 0.05), and slightly higher levels of LpB:C:E and LpA-II:B:C:D:E than controls. The levels of LpA-I:A-II were significantly lower (P < 0.01) in patients than controls. Fluvastatin treatment reduced all apoB-containing subclasses, but only the reduced level of LpB subclass was statistically significant (P < 0.02). The levels of LpA-I and LpA-I:A-II were not affected. Fluvastatin treatment reduced and normalized LpB and LpB:E subclasses. Although slightly reduced, the levels of markedly atherogenic LpB:C subclass were not normalized. The potential role of LpB:C on the progression of coronary artery disease in chronic renal insufficiency remains to be determined in future studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0085-2538
pubmed:author
pubmed:issnType
Print
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1865-71
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16572113-Aged, pubmed-meshheading:16572113-Apolipoproteins B, pubmed-meshheading:16572113-Body Height, pubmed-meshheading:16572113-Body Mass Index, pubmed-meshheading:16572113-Cohort Studies, pubmed-meshheading:16572113-Cross-Over Studies, pubmed-meshheading:16572113-Double-Blind Method, pubmed-meshheading:16572113-Fatty Acids, Monounsaturated, pubmed-meshheading:16572113-Female, pubmed-meshheading:16572113-Glomerular Filtration Rate, pubmed-meshheading:16572113-Humans, pubmed-meshheading:16572113-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:16572113-Indoles, pubmed-meshheading:16572113-Kidney Failure, Chronic, pubmed-meshheading:16572113-Lipoproteins, pubmed-meshheading:16572113-Male, pubmed-meshheading:16572113-Middle Aged, pubmed-meshheading:16572113-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency.
pubmed:affiliation
Lipid and Lipoprotein Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, 73104, USA. alaupovicp@omrf.ouhsc.edu
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't